| Literature DB >> 29284411 |
Jie-Wen Lei1, Xiao-Yu Ji2, Jun-Feng Hong1,3, Wan-Bin Li4, Yan Chen1, Yan Pan5, Jia Guo6.
Abstract
BACKGROUND: It is essential to accurately predict Postoperative liver failure (PHLF) which is a life-threatening complication. Liver hardness measurement (LSM) is widely used in non-invasive assessment of liver fibrosis. The aims of this study were to explore the application of preoperative liver stiffness measurements (LSM) by transient elastography in predicting postoperative liver failure (PHLF) in patients with hepatitis B related hepatocellular carcinoma.Entities:
Keywords: Hepatectomy; Hepatitis B; Hepatocellular carcinoma; Liver stiffness measurement; Posthepatectomy liver failure
Mesh:
Year: 2017 PMID: 29284411 PMCID: PMC5747264 DOI: 10.1186/s12876-017-0732-4
Source DB: PubMed Journal: BMC Gastroenterol ISSN: 1471-230X Impact factor: 3.067
Baseline characteristics of patients (N = 247)
| Variables | n (%), mean ± SD, or median (range) |
|---|---|
| Age (years) | 53.3 ± 10.3 |
| Gender (Male /Female) | 213/34(86%/14%) |
| BMI (kg /m2) | 29.9 ± 16.5 |
| Complicationsa | 43(17%) |
| Cirrhosis (yes /no) | 76/171(30.8%/69.2%) |
| White blood cell (109/l) | 5.2 ± 2.0 |
| Hemoglobin (g/l) | 143.9 ± 14.1 |
| Platelet Count (109/l) | 145(41–466) |
| Child–Pugh class A | 247 |
| Total bilirubin (umol/l) | 16.0 ± 11.8 |
| Albumin (g/l) | 41.7 ± 3.3 |
| Prealbumin (mg/l) | 238.6 ± 62.6 |
| Alanine transaminase (u/l) | 39.2 ± 34.2 |
| Aspartate aminotransferase (u/l) | 36.99 ± 31.3 |
| Gamma-glutamyl transpeptidase (u/l) | 47(11–866) |
| Alkaline phosphatase (u/l) | 81(34–250) |
| PT(s) | 11.5(9.4–15.4) |
| INR | 1.0(0.8–1.3)- |
| APTT(s) | 27.2(16.7–52.9) |
| LSM(Kpa) | 12.7(3.8–38.5) |
| Intraoperative blood infusion (yes / no) | 19/228(8%/92%) |
| Portal vein occlusion (yes / no) | 194/53(79%/21%) |
| Esophageal varices (yes / no) | 18/229(7.3%/92.7%) |
| Tumor capsule (yes / no) | 174/73(70%/30%) |
| Number of tumors (Single / multiple) | 217/30(88%/12%) |
| Anti-viral medication(Positive / negative) | 71/176(28.7%/71.2%) |
| HBV DNA levels (>1.0E + 04iu/ml/<1.0E + 04iu/ml) | 73/174(30%/70%) |
| Major hepatectomy | 40 (16%) |
| Median main tumor size(cm) | 5.02 ± 3.18 |
| Tumor location (right lobe /left lobe/ both) | 158/79/10(64%/32%/4%) |
aComplications include one or more of the following: hypertension, heart disease (myocardial ischemia, cardiomyopathy, arrhythmia), chronic obstructive pulmonary disease, diabetes, etc.
Univariate analysis and multivariate linear regression analysis of the variables associated with PHLF
| Variables | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| PLF(+)( | PLF(−)( |
| Exp(B) | OR95%CI |
| |
| Age (years) | 54.9 ± 10.9 | 53.0 ± 10.2 | 0.286 | |||
| Gender (Male /Female) | 33/4 (89%/11%) | 180/30 (86%/14%) | 0.572 | |||
| BMI (kg /m2) | 23.7 ± 3.1 | 23.3 ± 3.0 | 0.423 | |||
| White blood cell (109/l) | 4.9 ± 1.5 | 5.3 ± 2.1 | 0.275 | |||
| Hemoglobin (g/l) | 144.2 ± 12.3 | 143.8 ± 14.4 | 0.881 | |||
| Platelet Count (109/l) | 139.0 ± 79.9 | 155.3 ± 56.9 | 0.037 | |||
| Total bilirubin (umol/l) | 19.1 ± 8.8 | 15.4 ± 12.2 | 0.079 | |||
| Albumin (g/l) | 41.0 ± 3.6 | 41.9 ± 3.2 | 0.123 | |||
| Prealbumin (mg/l) | 218.2 ± 67.9 | 242.2 ± 61.0 | 0.032 | |||
| Alanine transaminase (u/l) | 43.2 ± 31.3 | 38.5 ± 34.7 | 0.449 | |||
| Aspartate aminotransferase (u/l) | 41.2 ± 23 | 36.1 ± 32.4 | 0.366 | |||
| Gamma-glutamyl transpeptidase (u/l) | 104.8 ± 148.6 | 68.6 ± 69.2 | 0.027 | |||
| Alkaline phosphatase (u/l) | 100.0 ± 47.4 | 83.2 ± 23.3 | 0.173 | |||
| PT(s) | 12.1 ± 1.2 | 11.6 ± 0.8 | 0.005 | |||
| INR | 1.0 ± 0.1 | 1.0 ± 0.1 | 0.005 | 1.065 | 1.014–1.119 | 0.013 |
| APTT(s) | 28.9 ± 5.9 | 27.1 ± 5.2 | 0.067 | |||
| LSM(kpa) | 21.4 ± 6.3 | 12.7 ± 5.7 | <0.001 | 1.211 | 1.134–1.293 | <0.001 |
| Intraoperative blood infusion (yes /no) | 7/30 (18.9%/81.1%) | 12/198 (5.7%/94.3%) | 0.005 | |||
| Portal vein occlusion (yes/no) | 24/13 (64.9%/35.1%) | 160/50 (76.2%/23.8%) | 0.145 | |||
| Number of tumors (Single/multiple) | 32/5 (86.5%/13.5%) | 185/25 (88.1%/11.9%) | 0.782 | |||
| Tumor capsule (yes/no) | 24/13 (64.9%/35.1%) | 150/60 (71.4%/28.6%) | 0.420 | |||
| HBV DNA levels (>1.0E + 04iu/ml/<1.0E + 04iu/ml) | 13/24 (35.1%/64.9%) | 60/150 (28.6%/71.4%) | 0.422 | |||
| Cirrhosis (yes/no) | 22/15 (59.5%/40.5%) | 54/156 (27.7%/74.3%) | <0. 001 | |||
| Esophageal varices (yes/no) | 7/30 (18.9%/81.1%) | 11/199 (5.2%/94.8%) | 0.003 | |||
| Major hepatectomy | 8 (22%) | 32 (15%) | 0.331 | |||
| Median main tumor size (cm) | 5.6 ± 4.0 | 4.9 ± 3 | 0.687 | |||
| Tumor location (right lobe/left lobe/both) | 29/6/2 (78.4%/16.2%/5.4%) | 129/73/8 (61.4%/34.8%/3.8%) | 0.082 | |||
Fig. 1ROC analysis of liver stiffness measurement for predicting PHLF
Fig. 2ROC analysis of liver stiffness measurement with only cirrhotic patients for predicting PHLF
Fig. 3ROC analysis of liver stiffness measurement for predicting cirrhosis
Fig. 4ROC analysis of INR for predicting PHLF
Fig. 5ROC analysis of model as the LSM-INR (LFM) index for predicting PHLF